文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

质子泵抑制剂在 GERD 治疗中的应用。

Proton pump inhibitors in the management of GERD.

机构信息

Jefferson Medical College, Albert Einstein Medical Center, Philadelphia, PA, USA.

出版信息

J Gastrointest Surg. 2010 Feb;14 Suppl 1:S62-6. doi: 10.1007/s11605-009-1015-3. Epub 2009 Sep 23.


DOI:10.1007/s11605-009-1015-3
PMID:19774429
Abstract

INTRODUCTION: Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief. RESULTS AND DISCUSSION: Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are "refractory" to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for "failure," is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy. CONCLUSION: Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.

摘要

简介:胃食管反流病(GERD)的治疗基于这样一种概念,即胃内容物(主要是胃酸和胃蛋白酶)是引起反流症状和食管损伤的原因。药物治疗的原理是控制胃内 pH 值将影响食管愈合,并随后缓解症状。

结果与讨论:通过使用抗分泌药物,主要是质子泵抑制剂(PPIs),可以控制 pH 值。大多数患者对 PPI 的每日单剂量有反应;然而,一些患者需要更高的剂量,而一小部分患者对这些药物的每日两次剂量“无反应”。这些药物的疗效,以及事实上“失败”的原因,可以通过了解 PPI 的作用机制以及剂量时间和进餐对其疗效的影响来阐明。

结论:长期使用 PPI 时,需要对其潜在副作用的新问题有充分认识,因为 GERD 是一种慢性病,大多数患者需要长期进行某种形式的药物治疗。本文回顾了 PPI 的药理特性及其对 GERD 治疗的影响。

相似文献

[1]
Proton pump inhibitors in the management of GERD.

J Gastrointest Surg. 2009-9-23

[2]
Lessons learned from intragastric pH monitoring.

J Clin Gastroenterol. 2001-8

[3]
Proton pump inhibitors in the management of gastroesophageal reflux disease.

Med Arh. 2011

[4]
Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo wireless esophageal pH monitoring study.

Rev Gastroenterol Mex. 2017

[5]
Drugs, bugs, and esophageal pH profiles.

Yale J Biol Med. 1999

[6]
Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.

J Clin Gastroenterol. 2011-10

[7]
ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?

Arq Gastroenterol. 2018-11

[8]
Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.

Expert Opin Pharmacother. 2010-6

[9]
Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy.

Dig Dis Sci. 2015-5

[10]
Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.

Gastroenterol Clin North Am. 2020-9

引用本文的文献

[1]
Pathogenesis of pepsin-induced gastroesophageal reflux disease with advanced diagnostic tools and therapeutic implications.

Front Med (Lausanne). 2025-2-19

[2]
MAGNETIC SPHINCTER AUGMENTATION DEVICE FOR GASTROESOPHAGEAL REFLUX DISEASE: EFFECTIVE, BUT POSTOPERATIVE DYSPHAGIA AND RISK OF EROSION SHOULD NOT BE UNDERESTIMATED. A SYSTEMATIC REVIEW AND META-ANALYSIS.

Arq Bras Cir Dig. 2024

[3]
Salivary pepsin as an independent predictor of treatment response for laryngopharyngeal reflux: prospective cohort study with multivariate analysis.

Sci Rep. 2023-12-21

[4]
[Current possibilities and challenges in the treatment of laryngopharyngeal reflux].

HNO. 2023-5

[5]
Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial.

Trials. 2022-10-18

[6]
Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.

Dig Dis Sci. 2018-11-21

[7]
Spotlight on the Linx™ Reflux Management System for the treatment of gastroesophageal reflux disease: evidence and research.

Med Devices (Auckl). 2018-8-31

[8]
Establishment of animal model of gastroesophageal reflux disease by per-oral endoscopic tunneling: a preliminary study.

J Thorac Dis. 2018-3

[9]
From Heartburn to Barrett's Esophagus, and Beyond.

World J Surg. 2017-7

[10]
Fewer acute respiratory infection episodes among patients receiving treatment for gastroesophageal reflux disease.

PLoS One. 2017-2-21

本文引用的文献

[1]
Use of proton pump inhibitors and risk of osteoporosis-related fractures.

CMAJ. 2008-8-12

[2]
Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.

Aliment Pharmacol Ther. 2007-3-1

[3]
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.

Aliment Pharmacol Ther. 2007-1-15

[4]
Long-term proton pump inhibitor therapy and risk of hip fracture.

JAMA. 2006-12-27

[5]
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

JAMA. 2005-12-21

[6]
Review article: proton pump inhibitors and bacterial overgrowth.

Aliment Pharmacol Ther. 2006-1-1

[7]
Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.

Aliment Pharmacol Ther. 2005-6-15

[8]
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.

Aliment Pharmacol Ther. 2005-3-15

[9]
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

JAMA. 2004-10-27

[10]
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.

CMAJ. 2004-7-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索